שווי מתואם לחוב ומזומנים: Cara Therapeutics Inc (CARA)
Cara Therapeutics, Inc. (CARA) focuses on developing treatments for pruritus in patients with renal failure, as evidenced by the price action visualized on GURU.Markets, where the Enterprise Value stands at -5.06. Drug deliveries are carried out through a network of specialized clinics. However, failed late-stage trials have undermined market advantages and investor confidence, effectively destroying the business's moat.
Cara Therapeutics, Inc. - פילוחים אנליטיים ומדדי מפתח (CARA)
The development of biopharmaceutical antipruritic drugs in compliance with ESG standards and bioethics is reflected in the dynamics of the business's fundamental value. This metric determines the real buyout price of Cara Therapeutics, Inc. (CARA) by summing the market capitalization with net debt (liabilities minus cash), allowing investors to objectively assess the asset by excluding market volatility and identifying the true enterprise value.